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There  is considerable current  interest  in  the development of techniques  for 
the precise manipulation of the immune response resulting in either enhancement 
or  suppression.  In  the  context  of responses  to  infectious  agents,  the  use  of 
molecules representing single defined epitopes able to substitute for antigen (i.e., 
surrogate antigens)  would provide considerable advantages over the use of the 
native antigen  (I-5). Two types of reagent could potentially fulfill this role, the 
first is a synthetic peptide antigen, and the second an internal  image antiidiotype 
mAb.  Because  of  the  development  of  the  technique  of  solid-phase  peptide 
synthesis and methods for the prediction  of potential antigenic determinants  of 
complex  antigens,  it  is  now  possible to  synthesize  peptides representing  these 
antigenic  determinants.  An  internal  image  antiidiotype  is  the  hypervariable 
region  of an antiidiotype  that  behaves as a  surface determinant  on the antigen 
with respect to recognition  by antibody.  A  number of such polyclonal reagents 
have  been  developed,  including  rabbit  antiidiotypic  antibodies  specific  for an 
interspecies  crossreactive idiotype on  antibodies  to hepatitis  B  surface antigen 
(6),  but  monoclonal  internal  image  antiidiotypes  appear  to  offer considerable 
advantages (7-13). 
Over 200 million individuals are persistently infected with the hepatitis B virus 
(HBV), 1 presenting  a  major  risk  of transmission  via  contaminated  blood  and 
blood products. In addition exposure to HBV is associated with the development 
of hepatocellular carcinoma late in life.  Hepatitis B is a particularly appropriate 
system in which  to investigate the potential  of surrogate antigenic  epitopes for 
immunization.  Vaccine  development  has  been  hindered  however,  as the  virus 
cannot  be  grown  in  vitro,  and  standard  virological  techniques  of  detecting 
neutralizing  antibody are not available.  The currently  licensed hepatitis  B vac- 
cines are therefore derived by extensive purification of the outer surface antigen 
of the virus (HBsAg), which is present  in excess in  the plasma of human  HBV 
carriers  (14).  New, alternative  sources of HBsAg include antigen  expressed in 
yeast by recombinant  DNA  technology (15).  It  is clearly  established  (16)  that 
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antibody  against  the  a  group  determinant,  which  occurs on  all  HBV  isolates 
regardless of subtype and on the HBsAg vaccine, is protective against infection. 
Because  of  the  wide  availability  of  sera  from  both  infected  individuals  and 
recipients  of the  licensed  vaccine,  as  well  as  the  availability  of a  number  of 
monoclonal and  polyclonal antibodies,  we  have  used  these antibodies  to assess 
the extent to which synthetic peptide antigens and antiidiotypes mimic antigens 
expressed  by  the  virus  and  recognized  by  the  immune  system.  Our  strategy 
includes measuring  the affinity of the antibody-antigen reaction, which  gives a 
valuable estimate of the closeness of fit of the antibody hypervariable regions to 
the antigenic epitope (17-18).  Such measurements therefore give an indication 
of the similarity of the surrogate antigenic epitope to that on the whole antigen 
that induced the antibody response in vivo. 
Herein, we have investigated the immunochemical characteristics of these two 
types of surrogate HBsAg antigenic epitopes consisting of (a) synthetic peptides 
representing amino acid residues  139-147, a  hydrophilic region corresponding 
to a part of the a determinant present on the 226-amino acid major polypeptide 
component of HBsAg, and (b) a panel of monoclonal antiidiotypes raised against 
anti-HBs mAb,  two of which  behave as an  internal  image of an a  determinant 
(19).  We demonstrate that these surrogate antigens  show concordance, in that 
the  internal  image  antiidiotypes  inhibit  the  binding  of both  monoclonal  and 
polycional anti-HBs antisera to the cyclical and linear peptide. 
Materials and Methods 
Antiidiotype  mAbs.  The  generation  and  maintenance  of these  antibodies  has  been 
described in detail elsewhere (19).  DE52-purified antibodies were radiolabelled by the 
chloramine T  method (20), and their antibody activities were assessed after radiolabelling 
by binding to idiotype-coated microtiter wells. 
HBsAg-related  Peptides.  A soluble complex from HBsAg was prepared by dissociation 
of native HBsAg particles with 2% Triton X°100 and separation by Con A-Sepharose 
chromatography (21).  This complex contains all the antigenic determinants present on 
the 25,000 tool wt (p25) and 30,000 tool wt (gp30) HBsAg polypeptides. Two synthetic 
peptides representing amino acids 124-137 and 139-147, regions of hydrophilicity in the 
HBsAg, were prepared by chemical synthesis. The sequences of the peptides are as follows. 
Peptide 124-137:  HzN-cys-met-thr-thr-ala-gln-gly-thr-ser-met-tyr-pro-ser-cys-tyr-COOH; 
peptide 139-147: H2N-cys-thr-lys-pro-thr-asp-gly-asn-cys-tyr-COOH.  These peptides were 
produced in both linear and cyclical forms, the latter by the formation of a disulfide bond 
between the two terminal cysteine residues. The introduction of a tyrosine residue at the 
C-terminus facilitated radiolabelling of the peptides. Both peptides reacted with standard 
reagents defining the a  region specificity, but  139-147  was bound by human anti-HBs 
antibodies with considerably higher affinity when in the cyclized form (17, 18). 
Anti-HBs Antibodies.  A panel of mAbs and polyclonal human, goat, rabbit, guinea pig, 
and swine anti-HBs antisera were used.  H3F5, a  mouse IgG2b anti-HBs mAb was the 
idiotype used for the generation of the antiidiotype mAbs.  This antibody recognizes a 
highly conserved epitope on every isolate of HBsAg studied.  It may thus be considered 
to be directed to an a determinant (22). H3F5 binds both the gp30 p25 complex and the 
cyclical  form of peptide  139-147,  but  with  low affinity (1.3  X  105 and  1.5  x  10S/M, 
respectively), but showed no reactivity with peptide 124-137. 
Fluid-phase  Inhibition  Assay.  Appropriate dilutions of anti-HBs antibodies giving 50% 
binding of a  constant amount of IzSI-labelled  linear or cyclical  peptide  139-147  were 
incubated with 0.2-5.0 #g of the purified antiidiotype mAbs. After incubation at 4°C for 
1 h, antibody-bound v25I-labelled peptide was determined by precipitation of the antibody- 
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percent  inhibition  of binding  of the  labelled  peptide  by the  anti-HBs antibody in  the 
presence of the monoclonal antiidiotype. 
Antibody Affinity Measurements.  The affinities of the anti-HBs antibody for the mono- 
clonal antiidiotypes and the affinities of the monoclonal antiidiotypes for the monoclonal 
anti-HBs idiotype were determined using ]25I-labelled  antibodies by modifications of the 
previously published method (23).  Complexes of anti-HBs and  ]2~I-labelled  antiidiotype 
and  of monoclonal  antiiodiotype and  12~I-labelled  monoclonal  anti-HBs  idiotype  were 
precipitated by PEG at a final concentration of 5%. The equilibrium constant or affinity 
(K) and the total antibody-combining site concentration  were calculated from a  modifi- 
cation of the Langmuir equation. Antibody affinity assays were performed in conditions 
of antigen  excess,  such  that  complexes composed of two  antigens  per antibody  were 
preferentially formed.  Under  these  conditions,  antibody affinity rather  than  avidity is 
measured, despite the divalency of the antiidiotype (24). 
Results 
Inhibition of Binding of Anti-HBs Antibodies to Synthetic Peptide 139-147 
and the gp30 p25 Complex by Antiidiotype mAbs 
The four antiidiotype mAbs (2F10, 4D4,  2E7, and  3H1) were used in assays 
to assess their ability to inhibit  the  binding of 125I-labelled  C139-147  (cyclical 
139-147) by a panel anti-HBs mAbs and a range of polyclonal anti-HBs antisera 
from  a  variety  of species (Fig.  1).  Inhibition  of binding  of C139-147  by the 
antibodies tested was obtained with both the 2F10 and 4D4 monoclonal antiidi- 
otypes. Previous studies using an immunofluorescence assay had also shown that 
these  two  antibodies  both  behave  as  internal  images  of an  a  determinant  of 
HBsAg (19). Internal image monoclonal antiidiotype 4D4 was, however, unable 
to inhibit  the  binding  of C139-147  by the  mouse anti-HBs mAbs  H29.4 and 
1329.2.3,  or by a  pool of anti-HBs Ig from human  convalescents. Antiidiotype 
2E7 was only able to inhibit the binding of C139-147 by the human and rabbit 
anti-HBs antisera.  Antiidiotype  3H1  did  not  inhibit  the  binding  of any  of the 
anti-HBs antibodies tested. 
The results expressed in  Fig.  1 represent the inhibition  of binding of C139- 
147  obtained  with  5  #g of the  purified  antiidiotype  antibody.  Curves  for the 
inhibition  of binding  by a  range  of antiidiotype  2F10  concentrations  of the 
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FIGURE  1.  Inhibition of binding of a panel of monoclonal and polyclonal anti-HBs antisera 
to the cyclical peptide  139-147  by approximately 5 ~g of monoclonal antiidiotypes. 60' 
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FIGURE 2.  Inhibition of binding of(A) monoclonal anti-HBs H29.4 and (B) polyclonal  human 
anti-HBs antibody to (i) the linear and (ii) the cyclical peptide  139-147  by the monoclonal 
internal image antiidiotype 2F 10. 
monoclonal anti-HBs and pooled human anti-HBs antibodies to both the  linear 
and cyclical forms of 139-147 are shown in Fig. 2. The 2FI0 was able to inhibit 
the  binding  of the  mouse  mAb  to both  linear and  cyclical  139-147  (Fig.  2a). 
Furthermore, the antiidiotype inhibited the binding of the  linear peptide more 
effectively than that of the cyclical peptide. The affinity of the monoclonal anti- 
HBs for the linear peptide was 2.1  x  10~/M; and for the cyclical peptide, 5.0  x 
10~/M. The inhibition of the binding of the pooled human anti-HBs to the linear 
and cyclical  forms of 139-147  by 2F10 (Fig.  2b) was lower than  that observed 
with  the mouse monoclonal anti-HBs, and was no higher than  28%.  Again,  tile 
binding of the linear peptide was inhibited to a  greater extent than the cyclical 
peptide.  The affinity of the  human  anti-HBs  for the  linear peptide  was  9.3  x 
10~S/M; and  for the cyclical  peptide,  9.1  x  107/M.  The binding  of the  pooled 
human  anti-HBs  lg to the  cyclical form of a  peptide representing amino acids 
124-137 of the y subtype of HBsAg could not be inhibited by antiidiotype mAb 
2F10 (Fig. 2b) or by 4D4 or 2E7 (data not shown). The binding of peptide  124- Anti-HBs 
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FIGURE  3.  Inhibition  of  binding  of anti-HBs  antisera  to  the  gp30p25  complex  by  four 
monoclonal antiidiotypes. 
TABLE  I 
Affinities of Monoclonal Antiidiotypes  for Anti-HBs ldiotype H3F5 
Affinity (K) for 
Antiidiotype  H3F5 idiotype 
2F10  3.2 X  108 
4D4  5.0 x  107 
2E7  1.4 X 108 
3H1  2.6 X  108 
H29.4 (irrelevant idiotype) 
137 by a  mouse monoclonal anti-HBs (192.75)  was not inhibited by any of the 
antiidiotypes (data not shown). 
The gp30  p25  polypeptide complex expresses all the antigenic repertoire of 
HBsAg. Both antiidiotypes 2F10 and 4D4 inhibited the binding of the gp30 p25 
complex by mouse, human, and swine anti-HBs antibodies (Fig. 3), but the levels 
of inhibition  were slightly lower than  those seen when the synthetic peptides 
were used as antigens. The binding of swine anti-HBs ad and ay antibodies to 
the gp30  p25  complex was inhibited by both  2F10  and 4D4.  However, these 
antiidiotypes did not inhibit the binding of the polypeptide complex by swine 
anti-y and anti-d antibodies,  confirming the similarity of the antiidiotypes and 
C139-147  to an a determinant(s) of HBsAg. Antiidiotype 2E7 was only able to 
inhibit the binding of gp30 p25 by the human anti-HBs. Antiidiotype 3H1  was 
unable to inhibit the binding of the polypeptide complex by any of the antibodies 
used. 
Affinity Measurements 
Affinity of the monoclonal antiidiotypes for the H3F5 anti-HBs idiotype.  The four 
monoclonal antiidiotypes all  bound  the  H3F5  idiotype (to which they are di- 
rected)  with  affinities ranging  from  5  X  107  to  3.2  X  108/M  (Table  I),  and 
differences between the four antibodies were small. 
Affinities of anti-HBs antisera for the surrogate antigens.  The affinities of human, 
rabbit, and goat polyclonal anti-HBs antisera for the surrogate antigens (antiidi- 
otypes and peptide  139-147)  were assessed and compared with their affinities 
for the gp30  p25  complex (Table II).  The affinities of these three polyclonal 232  SURROGATE  HEPATITIS  B  VIRUS  ANTIGENIC  EPITOPE 
TABLE  1I 
Affinities of Various Polyclonal Anti-HBs Antisera  for Surrogate Antigens and 
gp30 p25 Complex 
Anti-HBs antiserum 
Antigen 
Human convalescent 
pool  Rabbit  Goat 
Antibody- 
combining  Antibody-  Antibody- 
sites (pmol  K  combining  K  combining  K 
per 10 ¢*1  sites  sites 
serum) 
gp30 p25  198  3.0 ×  l07  172  1.2 X  107  279  3.5 x  107 
Cyclical  139-147  97  7.2 ×  107  ll0  3.3 x  10  v  160  1.4 X  107 
Linear  139-147  119  8.0 x  l06  106  9.0 x  106  189  5.9 ×  106 
2F10 antiidiotype  7.7  1.4 X  108  7.2  9.0 x  l0 s  12  8.4 ×  l0 s 
4D4 antiidiotype  --  6.7  2.0 x  108  11.8  6.6 x  l0 s 
2E7 antiidiotype  5.4  5.8 x  108  12.1  3.5 x  108  -- 
3H l  antiidiotype  --  --  -- 
antibodies for the  monoclonal  antiidiotypes  2F10,  4D4, and  2E7  ranged  from 
1.4 x  108 to 9  X  10S/M.  These values represent  high-affinity binding,  and are 
significantly higher than  those for the binding of the  139-147 peptide and the 
gp30 p25  polypeptide complex.  However, the  levels of such high-affinity  anti- 
bodies in  the sera  (expressed as pmol  of binding  sites) are considerably  lower 
than  the levels of the antibodies able to bind the peptide antigens.  The results 
of these binding studies are consistent with the data derived from the inhibition 
experiments (Fig.  1). Thus the human anti-HBs failed to bind 4D4, the goat anti- 
HBs failed to bind 2E7, and antiidiotype 3HI was not bound by any of the anti- 
HBs antisera. 
Discussion 
The studies reported here show that  the monoclonal antiidiotypes, shown by 
immunofluorescence to act as internal images of an HBsAg group a determinant, 
compete in inhibition  RIA with synthetic peptides representing the same deter- 
minant.  This is true not only with binding to monoclonal idiotypes derived from 
the mouse, but also with a  variety of polyclonal anti-HBs sera from human and 
several animal species. The competition by antiidiotype is restricted to the  139- 
147  peptide  representing  part  of the  a  group  determinant,  and  there  is  no 
influence on  the  binding  of a  peptide corresponding  with amino acid residues 
124-137 of the y subtype version of HBsAg. This confirms the results of previous 
studies,  in  which  swine  antisera  specific for  both  ay and  ad  determinants  lost 
their  ability to react with  internal  image antiidiotypes when antibody to the  a 
but not to the d or y determinants were absorbed out (25).  It is fascinating that 
antiidiotypes and peptides produced as surrogate antigens using different anti-a 
reagents should show convergence in having this property of mutual inhibition. 
The binding of the linear  139-147 peptide by the monoclonal and polyclonal 
anti-HBs was more readily inhibited by antiidiotype than  was the binding of the 
cyclical peptide, and this is consistent with a  lower affinity of the anti-HBs sera THANAVALA ET  AL.  233 
for the  linear form.  This  indicates that the  cyclized peptide  has a  reasonable 
similarity to the conformation of the native determinant on HBsAg, and that 
there  is  a  significant loss  of entropy in  adapting the  linear peptide  to fit the 
corresponding antibodies. 
Analysis of the binding curves revealed that the internal image antiidiotypes 
were bound with  higher affinity by the various mAb and heteroantisera than 
were  the  peptides.  In  addition,  one  might  envisage  that  the  intact  divalent 
antiidiotype molecule would be  bound by the  B cell surface receptors in  vivo 
with a higher avidity than would be expected with the presumably monovalent 
peptide. 
Of particular interest  was  the  finding that  levels of antibody, expressed  as 
picomoles of antigen-combining sites,  of polycional sera  for the peptides  was 
greater than that for the antiidiotype (Table II). This indicates that the peptide 
can combine with a  wider spectrum of the antibodies in a  polyclonal anti-HBs 
serum  than  can  the  antiidiotype,  which  is  therefore  more  restricted  in  its 
simulation of the original HBsAg. Further support for this view comes from the 
studies on competitive binding for polyclonal antibodies, in which the antiidiotype 
fails to produce  more  than a  relatively minor degree of inhibition of peptide 
binding, with inhibition reaching a plateau at ~20%.  The implication of these 
observations for the use of these surrogate antigens for potential vaccines is that, 
while antiidiotypes may be capable of stimulating B cells of higher affinity, they 
would react with a  more restricted range of B cell specificities than would the 
peptides. 
The plateau of inhibition with antiidiotype of the binding of cyclical peptide 
to polyclonal anti-HBs is lower than that obtained with the linear peptide. This 
suggests that, in addition to the affinity  considerations discussed earlier, a fraction 
of the anti-HBs serum may crossreact with antiidiotype and linear peptide, but 
not  with  the  cyclical  peptide.  Presumably,  the  constraints  on  conformation 
induced by cyclization preclude some but not all of the structures required to 
bind antibody, whereas the linear peptide is not subject to the same restrictions. 
The various monoclonal antiidiotypes give different patterns of inhibition with 
the group of monoclonal and polyclonal antibodies used in these studies. It may 
be useful to evaluate these different patterns in relationship to the analysis of the 
molecular basis  of internal image behavior (25).  We postulated that an antiidi- 
otype could resemble the antigen in terms of (a) mimickry of the contact residues 
used to bind antibody, (b) an obligatory set of residues on the antibody-combining 
site common to several different antibodies, or (c) an idiotype associated with 
but not part of the combining site. The latter seems to be excluded by the fact 
that all  the antiidiotypes were completely inhibited in their binding to idiotype 
by antigen, i.e., they are binding-site related. This leaves us with models based 
upon contact residues, either on the antigen or on the antibody, as in (a) and (b) 
above.  The  present  data  do  not  allow  us  to  differentiate between  these  two 
possibilities, but either model can account for the present findings on the basis 
of a minimum of three contact residues. In Table III, we have assumed that the 
antiidiotypes can mimic up to three contact residues on the peptide. The results 
can be accounted for by assuming that the various monoclonal antiidiotypes bear 
zero, one, two, or all three of the postulated antigenic contact residues on the 234  SURROGATE  HEPATITIS  B  VIRUS  ANTIGENIC  EPITOPE 
TABLE  lll 
Model to Account for lnternal Image Reactivities Based Upon 
Recognition of a Minimum of Three Contact Residues 
on HBsAg Peptides 
Antibodies 
Contact residues 
R1  R2  R3 
Anti-HBs 
Monoclonal 
H3F5  + 
H29.4 
1329.2:3 
Polyclonal 
Goat 
Guinea pig 
Swine 
l-|uman-vaccine~  + 
-convalescent pool  + 
Rabbit  + 
Anti-ld mAb 
2FI0  + 
4D4 
2E7  + 
3H1 
Residues bound by, anti-HBs 
+  + 
-  + 
-  + 
+  + 
+  + 
+  + 
+  + 
-  + 
+  + 
Residues mimicked by anti-Id 
+  + 
+ 
i 
peptide. Clearly, the mAb (2F10) with the maximum resemblance to the antigen 
and cyclical peptide  139-t47  would be likely to be a  valuable surrogate to use 
in a vaccine. 
It could be argued that the cluster of epitopes to which we loosely refer as the 
a  antigenic  determinant  might  best  be  simulated  in  a  potential  vaccine  by a 
synthetic  peptide  such  as  139-147  or  an  appropriate  cluster  of monoclonal 
internal  image antiidiotypes. 
Summary 
The use of molecules that represent single, defined epitopes able to substitute 
for antigen  (i.e.  surrogate antigens) offers considerable advantages over the use 
of native antigen for the precise manipulation  of the immune response. We have 
investigated the immunochemical  characteristics of two types of surrogate hep- 
atitis B surface antigen (HBsAg) epitopes: (a) linear and cyclical synthetic peptides 
representing amino acid residues  139-147, a hydrophilic region corresponding 
to part of the a determinant of the HBsAg, and (b) four monoclonal antiidiotypes 
raised against anti-HBs mAb, two of which behave as an internal  image of an a 
determinant. 
Polyclona] anti-HBs antisera bound the monoclonal antiidiotypes with affinities 
of" the  order  of  10S/M,  and  to  the  peptides  with  >10-fold  lower  affinities. 
However, the  levels of antibody in the polyclonal antisera  for the peptides was THANAVALA  ET  AL.  235 
greater than for the antiidiotypes. In inhibition RIA, the surrogate antigens show 
concordance in that the internal  image antiidiotypes inhibit the binding of both 
monoclonal and polyclonal anti-HBs to the linear and cyclical 139-147  peptides. 
These results imply that surrogate antigens could indeed be useful as potential 
hepatitis  vaccines,  but  while  the  antiidiotypes  may stimulate  B  cells  of higher 
affinity, they would react with a  more restricted range of B cell reactivities than 
would the peptides. A future HBV vaccine may thus comprise a synthetic peptide 
such as cyclical  139-147  or a cluster of monoclonal internal image antiidiotypes. 
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